Clinical Trials
14
Active:0
Completed:4
Trial Phases
4 Phases
Phase 1:5
Phase 2:2
Phase 3:4
+1 more phases
Drug Approvals
76
PHILIPPINES:76
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (35.7%)Phase 3
4 (28.6%)Not Applicable
3 (21.4%)Phase 2
2 (14.3%)Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients
Not Applicable
Recruiting
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Target Recruit Count
- 28
- Registration Number
- NCT07096869
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Study of SYH2062 Injection in Healthy Chinese Volunteers
Phase 1
Recruiting
- Conditions
- Healthy Chinese Volunteers
- Interventions
- Drug: SYH2062 injectionDrug: SYH2062-Matching placebo
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-04-30
- Target Recruit Count
- 46
- Registration Number
- NCT06842537
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Peking Union Medical College Hospital, Beijing, Beijing, China
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Phase 3
Not yet recruiting
- Conditions
- Post-operative Nausea and Vomiting (PONV)
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 486
- Registration Number
- NCT06543966
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2025-04-04
- Target Recruit Count
- 39
- Registration Number
- NCT06229548
- Locations
- 🇨🇳
10 Chedaogou Rd.,Haidian District, Beijing, China, Beijing, Beijing, China
A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
Phase 3
Not yet recruiting
- Conditions
- High-risk (Secondary) Acute Myeloid Leukemia
- Interventions
- Drug: Liposomal cytarabine-daunorubicin for injectionDrug: 7+3 (cytarabine and daunorubicin)
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2023-12-28
- Target Recruit Count
- 120
- Registration Number
- NCT06182592
- Locations
- 🇨🇳
Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, China
- Prev
- 1
- 2
- 3
- Next
News
No news found